67.79
+0.56%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ANI Pharmaceuticals
From its filings with the US Securities and Exchange Commission
ANI Pharmaceuticals is based in Princeton, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ANIP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $883.4m and net income of $78.3m. At that date it held total assets of $1.44bn and shareholders' equity of $540.7m.
ANI Pharmaceuticals is a diversified bio-pharmaceutical company. The Company's mission is “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing therapeutics through its Rare Disease, Generics, and Brands businesses.
During March 2025, the FDA approved an expanded label for ILUVIEN to include an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye ("NIU-PS") in addition to the then-current indication of Diabetic Macular Edema ("DME"). The Company is currently marketing ILUVIEN for both indications in the U.S. ILUVIEN was already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries. During the second quarter of 2025, the Company transitioned promotional efforts in the U.S. from YUTIQ to ILUVIEN with its combined label of DME and NIU-PS.
On August 13, 2024, the Company entered into a credit agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the financial institutions party thereto as lenders (the "2024 Credit Agreement"), which provides for aggregate principal commitments consisting of (i) a senior secured delayed-draw term loan facility in an aggregate principal amount of $325.0 million, and (ii) a senior secured revolving credit facility in an aggregate commitment amount of $75.0 million, which may be used for revolving credit loans, swingline loans and letters of credit.
Quoted from its 10-K, filed 27 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 4 May 2000
- Employees
- 970
- Website
- anipharmaceuticals.com ↗
- Head office
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Patrick WalshIndependent Chairman of the Board, since 2018$373,891
- Mr. Nikhil LalwaniPresident, Chief Executive Officer, Director, since 2020$8.9m
- Mr. Stephen CareyChief Financial Officer, Senior Vice President - Finance$2.9m
- Ms. Krista DavisChief Human Resources Officer, Senior Vice President
- Ms. Meredith CookSenior Vice President, General Counsel, Corporate Secretary$2.0m
- Mr. Chad GassertSenior Vice President - Corporate Development and Strategy$1.9m
- Mr. Ori GutwergSenior Vice President - Generics$2.1m
- Mr. Christopher MutzSenior Vice President, Head of Rare Diseases$2.4m
- Mr. Thomas RowlandSenior Vice President, Head of Established Brands
- Mr. Muthusamy ShanmugamDirector, Head of Research and Development, Chief Operating Officer - Novitium Operations, since 2021
- Mr. Thomas HaugheyIndependent Director$363,891
- Mr. Matthew LeonardIndependent Director$349,598
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 29
- Environment
- 8
- Social
- 35
- Governance
- 46
- Women in the workforce
- 42%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ANI Pharmaceuticals Inc has several strengths that contribute to its success and competitive advantage. These include:
Weaknesses
- Despite its strengths, ANI Pharmaceuticals Inc also faces a few weaknesses and challenges that need to be addressed:
Opportunities
- ANI Pharmaceuticals Inc can capitalize on the following opportunities to drive future growth and innovation:
Threats
- ANI Pharmaceuticals Inc should be aware of the following threats that could potentially impact its business:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.